SGM
MPLT

Seven Grand Managers’s MapLight Therapeutics MPLT Stock Holding History

Seven Grand Managers’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.58M Hold
100,000
– – 0.14% 111
2026
Q1 		$2.03M Hold
100,000
– – 0.14% 112
2025
Q4 		$1.76M Buy
+100,000
New +$1.68M 0.13% 114

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Seven Grand Managers's MPLT Position: Q2 2026 in Review

Seven Grand Managers held its MapLight Therapeutics (MPLT) position steady in Q2 2026 at 100,000 shares worth $3.58M. The position accounts for 0.14% of the portfolio, ranked #111.

Seven Grand Managers first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 106 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Seven Grand Managers held 100,000 shares of MapLight Therapeutics worth $3.58M as of Q2 2026.
  • Seven Grand Managers left its MapLight Therapeutics share count unchanged in Q2 2026.
  • MapLight Therapeutics made up 0.14% of Seven Grand Managers's portfolio in Q2 2026, its #111 holding.
  • Seven Grand Managers first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 106 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Seven Grand Managers's 13F filing for Q2 2026, filed 14 Aug 2026.